Biotech2 hours ago
Johnson & Johnson’s Tecvayli Combo Shows Breakthrough Results in Multiple Myeloma
Johnson & Johnson’s Phase 3 MajesTEC-3 study shows that the combination of teclistamab and subcutaneous daratumumab (tec+dara) significantly improves outcomes for relapsed or refractory multiple myeloma...